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950Dual antiplatelet therapy (clopidogrel and aspirin)
is associated with increased all-cause mortality after
carotid revascularization for asymptomatic carotid
disease
Francisco Alcocer, MD, Zdenek Novak, MD, Bart R. Combs, MD, Bruce Lowman, MD,
Marc A. Passman, MD, Marjan Mujib, MD, and William D. Jordan, MD, Birmingham, Ala
Objective: Despite the established guidelines, there is not a clear consensus about how to manage antiplatelet therapy after
carotid surgery. It is a common practice in vascular surgery to use the combination of aspirin and clopidogrel in the
treatment of such patients. In this work, we analyzed the impact on long-term survival of antiplatelet therapy in patients
treated for carotid stenosis at a single institution over a 10-year period.
Methods: Outcomes of 471 patients who underwent carotid intervention (1999-2008) were analyzed. Discharge pre-
scription summaries were retrieved, and patients were divided into two groups according to their antiplatelet regimen:
aspirin-only group and aspirin plus clopidogrel group. Only patients with a minimum of 30 days of conﬁrmed antiplatelet
therapy were included. All-cause mortality during follow-up represented the primary outcome, whereas stroke and
bleeding at 30 days and during follow-up represented secondary end points. When local records were sparse, the Social
Security Death Index was queried to conﬁrm mortality. The International Classiﬁcation of Diseases, 9th Revision (ICD-9
codes), was reviewed for treatment related to a bleeding condition.
Results: When divided by indication, there was an increased mortality rate in patients with asymptomatic carotid disease
receiving dual antiplatelet therapy as compared with aspirin alone (47% vs 40%; P [ .05). Patients with symptomatic
carotid disease had a nonsigniﬁcant decrease in all-cause mortality if they received dual antiplatelet therapy (38% vs 39%;
P [ .53). In a subgroup analysis, there was a signiﬁcant increase in the rate of all-cause mortality among patients older
than 75 years receiving dual antiplatelet therapy for asymptomatic carotid disease (82% vs 56%; P[ .001), whereas there
was a nonsigniﬁcant decrease in mortality in patients older than 75 years receiving dual antiplatelet therapy for symp-
tomatic carotid disease (47% vs 63%; P [ .50). There was no difference in secondary outcomes (stroke and bleeding)
regardless of the indication or the antiplatelet therapy.
Conclusions: In this retrospective, single-institution study, the use of dual antiplatelet therapy (aspirin plus clopidogrel) in
patients intervened for asymptomatic carotid disease was related to increased all-cause mortality, whereas it did not
signiﬁcantly inﬂuence the outcome in patients with symptomatic carotid disease. (J Vasc Surg 2014;59:950-5.)The beneﬁcial effect of antiplatelet therapy for the
management and prevention of noncardioembolic stroke
has been extensively studied. Although monotherapy
(aspirin or clopidogrel) is widely accepted for secondary
and primary stroke prevention (ie, with and without previ-
ous ischemic brain symptoms, respectively) dual therapy
(aspirin and clopidogrel), which has a pivotal role in coro-
nary artery disease (CAD), has become less clear for stroke
prevention and possibly hazardous because of increased
bleeding risk. Despite the established guidelines, there isthe Section of Vascular Surgery and Endovascular Therapy, University
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therapy after carotid surgery. It is a common practice in
vascular surgery to use the combination of aspirin and clo-
pidogrel in the treatment of such patients. In this work, we
analyzed the impact on long-term survival of antiplatelet
therapy in patients treated for carotid stenosis at a single
institution over a 10-year period.
METHODS
A prospectively maintained vascular database was
queried for patients undergoing carotid endarterectomy
(CEA) or carotid angioplasty and stenting (CAS) for carotid
stenosis at the University of Alabama at Birmingham from
January 1999 through December 2008. Patients were fol-
lowed up to January 2012. Asymptomatic carotid disease
was deﬁned as internal carotid artery stenosis$60% in a pa-
tient with absence of ipsilateral neurological symptoms for at
least 6 months before the procedure.1 Symptomatic carotid
disease was deﬁned as internal carotid stenosis $50% in a
patient with ipsilateral neurological symptoms within
6 months of admission. The degree of carotid stenosis was
determined primarily by ultrasound and selectively
Table I. Baseline characteristics
Variables
All patients
(N ¼ 471), No. (%)
Symptomatic carotid disease
(n ¼ 211), No. (%)
Asymptomatic carotid disease
(n ¼ 260), No. (%)
Aspirin only
(n ¼ 295)
Clopidogrel
plus aspirin
(n ¼ 176)
Aspirin only
(n ¼ 121)
Clopidogrel
plus aspirin
(n ¼ 90)
Aspirin only
(n ¼ 174)
Clopidogrel
plus aspirin
(n ¼ 86)
Age, years 69 6 9 67 6 10 67 6 10 66 6 11 70 6 9 69 6 8
Female 116 (39) 70 (40) 53 (44) 38 (42) 63 (36) 32 (37)
Nonwhites 21 (7) 13 (7) 11 (9) 6 (7) 10 (6) 7 (8)
Current smokers 65 (22) 40 (23) 22 (18) 22 (24) 43 (25) 18 (21)
Coronary intervention 101 (34.2) 76 (43) 36 (30) 35 (39) 65 (37) 41 (48)
Carotid stenting 11 (3.7) 66 (38)a 4 (3) 40 (44.4)a 7 (4) 26 (30)a
DM 85 (29) 56 (32) 22 (18) 28 (31)a 63 (36) 28 (33)
Hypertension 207 (70) 136 (77)a 74 (61) 65 (72)a 133 (76) 71 (83)
HLD 155 (53) 116 (66)a 54 (45) 56 (62)a 101 (58) 60 (70)
Statins 141 (48) 88 (50) 40 (43) 33 (37)a 101 (58) 55 (64)
Prior stroke 52 (18) 39 (22) 36 (30) 26 (29) 16 (9) 13 (15)
Peripheral arterial disease 25 (9) 26 (15)a 8 (7) 14 (16)a 17 (10) 12 (14)
COPD 29 (10) 23 (13) 15 (12) 9 (10) 14 (8) 14 (16)
Dialysis 6 (2) 3 (2) 3 (3) 1 (1) 3 (2) 2 (2)
COPD, Chronic obstructive pulmonary disease; DM, diabetes mellitus; HLD, hyperlipidemia.
Continuous data are presented as mean 6 standard deviation and categorical data as number (%).
aP < .05.
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angiogram, or by magnetic resonance imaging, on the basis
of surgeon preference. Hospital computerized records,
ofﬁce charts, and telephone records were reviewed. Demo-
graphics and clinical data were collected. Discharge prescrip-
tion summaries were retrieved, and patients were divided
into two groups, according to their antiplatelet regimen:
aspirin-only group and aspirin plus clopidogrel group.
Only patients with a minimum of 30 days of conﬁrmed anti-
platelet therapywere included. In each clinical visit, the phar-
macy records were obtained to verify continuation of the
antiplatelet therapy. Patients were excluded for any of the
following reasons: (1) patients discharged on aspirin but
also taking clopidogrel afterward for different indication
such as drug eluting coronary stent, (2) crossovers from indi-
cation (symptomatic to asymptomatic or the opposite),
(3) simultaneous coronary artery bypass grafting, and
(4) incomplete information for analysis. For patients with
two procedures with the same indication, only the second
intervention was considered for analysis. All-cause mortality
during follow-up represented the primary outcome, whereas
stroke and bleeding at 30 days and during follow-up repre-
sented secondary end points. The Social Security Death In-
dex (SSDI) was reviewed for all patients lost to follow-up
for more than 12 months, and the International Classiﬁca-
tion of Diseases, 9th Revision (ICD-9 codes), was reviewed
for treatment related to a bleeding condition.
Deﬁnitions. Diabetes mellitus (DM): Any patient with
established diagnosis and taking oral hypoglycemic medica-
tions or insulin.
CAD: Patients with previous coronary artery interven-
tions (either surgery or angioplasty and stenting).
Chronic kidney disease: Based on glomerular ﬁltration
rate (mL/min per 1.75 m2) and adjusted for race and sexby means of the isotope dilution mass spectrometry-
traceable Modiﬁcation of Diet in Renal Disease Study equa-
tion according to theNational Kidney Foundationguidelines
and staged according to the National Kidney Foundation
guidelines2 and deﬁned as glomerular ﬁltration rate <60.
End-stage renal disease: Patients receiving dialysis.
Chronic obstructive pulmonary disease (COPD): Any
patient with established diagnosis at the time of surgery,
based on medical records diagnosis.
Hyperlipidemia (HLD): Any patient with established
diagnosis at the time of surgery.
Peripheral arterial disease: History of leg revasculariza-
tion or documentation of ankle-brachial index <0.9.
Major bleeding: Fatal bleeding, intracranial hemor-
rhage, or bleeding that caused hemodynamic compromise
requiring blood or ﬂuid replacement, inotropic support,
or surgical intervention.
Minor bleeding: Any bleeding that did not meet the
criteria for major bleeding.3
Statistical analysis. Descriptive univariate statistical
analysis with data reported as mean 6 standard deviation
is used. Comparisons between continuous variables were
performed with the use of a two-tailed t-test with categor-
ical variable comparisons performed bymeans of c2 analyses.
Multivariate Cox proportional-hazards regression analysis
and Kaplan-Meier survival analysis were used to determine
the impact of antiplatelet treatment on all-cause mortality
during 5 years of median follow-up. The following variables
were included in the model: aspirin, aspirin plus clopidogrel,
age, race, hypertension, HLD, COPD, DM, CAD, chronic
kidney disease, peripheral arterial disease, carotid stenting,
and smoking. Results are reported as hazard ratios (HRs)
with 95% conﬁdence intervals (CIs). A P < .05 level of
statistical signiﬁcance was used.
Table II. Association of antiplatelet therapy with mortality
All-cause mortality
Events, No. (%)
Absolute risk
differencea HRb (95% CI) P valueAspirin only Clopidogrel plus aspirin
All patients 295 176
Unadjusted 117 (40) 74 (42) þ2% 0.74 (074-1.19) .94
Multivariable adjusted 1.22 (0.86-1.72) .247
Symptomatic carotid patients 121 90
Unadjusted 47 (39) 34 (38) 1% 0.95 (0.54-1.67) .43
Multivariable adjusted 0.53 (0.47-1.46) .53
Asymptomatic carotid patients 174 86
Unadjusted 70 (40) 40 (47) þ7% 1.29 (0.76-2.17) .16
Multivariable adjusted 1.55 (0.98-2.44) .05
CI, Conﬁdence interval; HR, hazard ratio.
aAbsolute risk differences were calculated by subtracting percent events in patients who received aspirin only from those in patients receiving aspirin plus
clopidogrel therapy.
bHRs comparing patients receiving aspirin only vs those receiving clopidogrel plus aspirin.
Fig 1. Kaplan-Meier plots for all-cause mortality for patients with asymptomatic carotid disease. HR, Hazard ratio;
CI, conﬁdence interval.
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Between January 1998 and December 2008, 905 ca-
rotid revascularizations were identiﬁed in 849 patients
(746 CEA and 159 CAS). Two hundred sixty asymptom-
atic and 211 symptomatic unique patients fulﬁlled the in-
clusion criteria for this study (394 CEA and 77 CAS).
Demographic and clinical data are summarized inTable I. The mean age of all patients was 67.9 (69.4)
years, and 186 (39.5%) patients were female. The median
follow-up time of all patients was 51.71 months (range,
1-154 months). In the symptomatic group, patients were
more likely to receive dual antiplatelet therapy if CAS was
performed and in the presence of DM, hypertension, and
HLD. In the asymptomatic group, patients were more
Fig 2. Kaplan-Meier plots for all-cause mortality for patients with symptomatic carotid disease. HR, Hazard ratio;
CI, conﬁdence interval.
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formed and in the presence of COPD.
Follow-up toward the primary end point (all-cause mor-
tality) showed no difference in mortality among patients
with dual antiplatelet therapy or aspirin alone in the entire
cohort. However, when divided by indication, there was
an increased mortality rate in patients with asymptomatic
carotid disease receiving dual antiplatelet therapy as
compared with aspirin alone (47% vs 40%; P¼ .05). Patients
with symptomatic carotid disease had a nonsigniﬁcant
decrease in all-cause mortality if they received dual antiplate-
let therapy (38% vs 39%; P ¼ .53; Table II). When dual an-
tiplatelet therapy was compared with aspirin alone in
asymptomatic patients by means of Cox regression survival
analysis, dual therapy was nonsigniﬁcantly and indepen-
dently associated with increased all-cause mortality (HR,
1.55; 95% CI, 0.98-2.44; P ¼ .059), whereas it had a
nonsigniﬁcant decreased mortality rate in symptomatic dis-
ease (HR, 0.53; 95% CI, 0.47-1.46; P ¼ .53; Figs 1 and 2).
In a subgroup analysis, there was a signiﬁcant increase in the
rate of all-causemortality among patients older than 75 years
receiving dual antiplatelet therapy for asymptomatic carotid
disease (82% vs 56%; P ¼ .017), whereas there was a
nonsigniﬁcant decrease in mortality in patients older than
75 years receiving dual antiplatelet therapy for symptomaticcarotid disease (47% vs 63%; P ¼ .15). When dual antiplate-
let therapy was compared with aspirin alone in asymptom-
atic patients older than 75 years in Cox regression survival
analysis, it was signiﬁcantly and independently associated
with all-cause mortality (HR, 4.27; 95% CI, 1.94-9.37;
P < .001). Conversely, there was no difference in mortality
among patients younger than 75 years regardless of the indi-
cation or the antiplatelet therapy (Table III). There was no
difference in secondary outcomes (stroke and bleeding)
regardless of the indication (asymptomatic vs symptomatic)
or the antiplatelet therapy (dual vs aspirin only) (Table IV).
DISCUSSION
In this retrospective, single-institution study, the use of
dual antiplatelet therapy (aspirin plus clopidogrel) in pa-
tients intervened for asymptomatic carotid disease was
related to increased all-cause mortality, whereas it did not
signiﬁcantly inﬂuence the outcome in patients with symp-
tomatic carotid disease. This study supports the results
of the CARISMA trial,4 in which dual antiplatelet therapy
was associated with increased bleeding and increased
all-cause mortality in patients with asymptomatic vascular
conditions, including cerebrovascular disease.
This review was undertaken in patients who received
intervention in a 10-year period, before or at the time
Table III. Association of antiplatelet therapy with mortality by age
All-cause mortality
Events, No. (%)
Absolute risk
differencea HRb (95% CI) P valueAspirin only Clopidogrel plus aspirin
<75 years
Symptomatic carotid patients 91 75
Unadjusted 36 (30.8) 27 (36.0) 5.2% 1.26 (0.65-2.43) .240
Multivariable adjusted 0.65 (0.32-1.33) .245
Asymptomatic carotid patients 122 64
Unadjusted 41 (33.6) 22 (34.4) 0.8% 1.03 (0.54-1.95) .520
Multivariable adjusted 1.49 (0.78-2.83) .217
$75 years
Symptomatic carotid patients 30 15
Unadjusted 22 (63.3) 7 (46.7) 16.6% 0.51 (0.13-1.85) .155
Multivariable adjusted 1.50 (0.44-5.05) .507
Asymptomatic carotid patients 52 22
Unadjusted 36 (55.8) 18 (81.8) 26% 3.56 (1.08-13.58) .017
Multivariable adjusted 4.27 (1.94-9.37) <.001
CI, Conﬁdence interval; HR, hazard ratio.
aAbsolute risk differences were calculated by subtracting percent events in patients who received aspirin only from those in patients receiving aspirin plus
clopidogrel therapy.
bHRs comparing patients receiving aspirin only vs those receiving clopidogrel plus aspirin.
Table IV. Association of antiplatelet therapy with other
outcomes
Outcomes
Events, No. (%)
P value
Aspirin
only
Clopidogrel
plus aspirin
All patients (n ¼ 471)
Stroke, 30 days 5 (1.7) 4 (2.3) .999
Stroke, long term 6 (2.0) 4 (2.3) .999
Major bleeding 5 (1.7) 2 (1.1) .335
Minor bleeding 20 (6.7) 15 (8.5) .244
Symptomatic carotid
patients (n ¼ 211)
Stroke, 30 days 1 (0.8) 2 (2.2) .233
Stroke, long term 3 (2.5) 1 (1.1) .267
Major bleeding 2 (1.6) 0 (0.0) .325
Minor bleeding 9 (7.4) 6 (6.7) .421
Asymptomatic carotid
patients (n ¼ 260)
Stroke, 30 days 4 (2.3) 2 (2.3) .999
Stroke, long term 3 (1.7) 3 (3.5) .457
Major bleeding 3 (1.72) 2 (2.3) .999
Minor bleeding 11 (6.3) 9 (10.5) .127
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this time, it is likely that in the “real world,” vascular sur-
geons may still overuse antiplatelet agents after carotid pro-
cedures. With perioperative stroke being the most feared
complication after carotid intervention, assurance of full
platelet inhibition is of utmost importance. Although the
routine use of antiplatelet drugs after carotid surgery has
been supported by several studies,7,8 the ideal antiplatelet
regimen (which medication and what duration) has not
yet been well documented. In contrast, there is strong ev-
idence for the medical recommendation for noncardioem-
bolic ischemic stroke prevention.9,8,11
A critical aspect to adequately interpreting the re-
sults of this work is the discrimination of the carotid inter-
vention according to their stroke prevention intent. Also,
a distinction must be made between perioperative man-
agement and long-term prevention. Regardless of the
technique (surgery or endovascular), intervention for
asymptomatic and symptomatic patients should be consid-
ered as primary and secondary prevention, respectively,
and the coupled long-term antiplatelet treatment should
follow recommended guidelines. In primary prevention,
the use of antiplatelet drugs (mainly aspirin) is generally
accepted,10 although it has been challenged because
the beneﬁcial effects may be offset by an increase in
bleeding.11 Clopidogrel has a lower incidence of gastroin-
testinal bleeding and may be more effective in diabetics
or those with clinical aspirin resistance. After surgery,
however, aspirin has been shown to reduce the incidence
of stroke12,13 and remains the drug against which no other
has clearly shown superiority. Single antiplatelet therapy
(mainly aspirin or clopidogrel) is recommended after
carotid intervention for asymptomatic disease (primary
prevention) and should be continued indeﬁnitely after-
ward only for patients at high risk of other vascular athero-
sclerotic events.14,15 Regarding dual antiplatelet therapyfor primary prevention, there are no data to support its
use, and it may cause harm unless there is some other indi-
cation such as a drug-eluting stent.
In the CARISMA trial, the hypothesis of beneﬁt from
dual antiplatelet therapy for primary prevention failed and
rendered elevated mortality rates. Currently, the only estab-
lished indication for dual therapy after carotid intervention
is carotid stenting, and the optimal duration should generally
not exceed 30 days after the procedure.16 For secondary pre-
vention, aspirin, clopidogrel, or aspirin plus dipyridamole are
all adequate options for initial therapy. Aspirin is favored
because of its lower cost, unless there is speciﬁc contraindica-
tion. Renal insufﬁciency may be considered an indication to
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let therapy (usually aspirin) is suggested for the postoperative
period. Even though the combination of aspirin and
clopidogrel is not routinely recommended, dual therapy has
been shown to signiﬁcantly reduce asymptomatic microem-
bolization in actively embolizing patients with symptomatic
carotid stenosis, particularly around the time of interven-
tion.17 Likewise, the CARISMA trial suggested potential
beneﬁt in patients with established, symptomatic vascular
conditions, including cerebrovascular disease. The reason
that dual antiplatelet therapy increases mortality in asymp-
tomatic but not in symptomatic patients is unknown; howev-
er, the authors on that trial suggest that patients with
established vascular diseasemay have a lower risk for bleeding
fromdual antiplatelet administration.Our results also suggest
a possible beneﬁt in symptomatic patients, although it did not
reach statistical signiﬁcance. Perhaps patients with symptom-
atic disease have a higher burden of disease and/or more
active platelets and can beneﬁt from dual antiplatelet therapy.
Findings in that trial and reproduced in this study should
discourage the use of dual therapy in asymptomatic carotid
disease unless there is another indication for dual therapy.
Study limitations. Some limitations exist in this retro-
spective, small sample study. First, it is difﬁcult to discern
medication compliance for many patients through the
entire study. Second, the incidence of late bleeding could
not always be accurately determined because it was retrieved
by ICD-9 codes, which include only patients seen in our
hospital during follow-up. Third, the cause of death could
not be determined in many patients whose information was
retrieved by SSDI, and ﬁnally, we did not identify patients
who could have been resistant to aspirin or clopidogrel.
CONCLUSIONS
Theuse of dual antiplatelet therapy in patients treated for
asymptomatic carotid disease is associated with higher long-
term mortality than in single drug use such as aspirin. Dual
therapy did not provide reduced stroke risk and thus should
be carefully used in patients with limited vascular disease.
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